Trastuzumab Deruxtecan (Enhertu)
Canadian Journal of Health Technologies · 17.06.2026 · 6 (6)
DOI: 10.51731/cjht.2026.1458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 17.06.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses Trastuzumab deruxtecan (Enhertu), powder for concentrate for solution for IV infusion (100 mg vial). Indication: For the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
Zitieren
APA
CDA-AMC (2026). Trastuzumab Deruxtecan (Enhertu). Canadian Journal of Health Technologies, 6(6). https://doi.org/10.51731/cjht.2026.1458
Vancouver
CDA-AMC. Trastuzumab Deruxtecan (Enhertu). Canadian Journal of Health Technologies. 2026;6(6). doi:10.51731/cjht.2026.1458
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Trastuzumab Deruxtecan (Enhertu)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {6},
doi = {10.51731/cjht.2026.1458}
}
EUVIMED